샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798174

세계의 핵산 기반 치료 시장

Nucleic Acid Based Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 291 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 핵산 기반 치료 시장은 2030년까지 126억 달러에 도달

2024년에 54억 달러로 추정되는 세계의 핵산 기반 치료 시장은 2024-2030년에 CAGR 15.1%로 성장하며, 2030년에는 126억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 RNA 간섭·단쇄간섭 RNA는 CAGR 16.3%를 기록하며, 분석 기간 종료까지 85억 달러에 달할 것으로 예측됩니다. 안티센스 올리고뉴클레오티드 분야의 성장률은 분석 기간의 CAGR로 13.3%로 추정됩니다.

미국 시장은 15억 달러로 추정되는 한편, 중국은 CAGR 20.2%로 성장할 것으로 예측

미국의 핵산 기반 치료 시장은 2024년에는 15억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 28억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 20.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 11.0%와 13.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.0%로 성장할 것으로 예측됩니다.

세계의 핵산 기반 치료 시장 - 주요 동향과 촉진요인 정리

핵산 치료제는 질병 치료의 미래를 어떻게 재정의하고 있는가?

핵산 기반 치료는 유전자 발현과 세포 기능의 정밀한 조작을 가능하게 함으로써 현대의학을 재구성하고 있습니다. 안티센스 올리고뉴클레오티드(ASO), 저분자 간섭 RNA(siRNA), 마이크로 RNA(miRNA), 압타머, 메신저 RNA(mRNA) 등을 포함한 이러한 치료법은 기존의 단백질에 초점을 맞춘 접근법을 우회하여 유전자 수준에서 표적화된 개입을 제공합니다. 제공합니다. 번역 후 단백질 경로를 조절하는 기존 약물과 달리, 핵산 치료제는 전사와 번역의 초기 단계인 전사 및 번역 단계에 개입하므로 유전자의 기능 장애를 교정하는 데 매우 높은 특이성을 발휘합니다.

이 혁신적인 접근법은 비암호화 RNA, 유전자 융합, 희귀 단일 유전자 질환 등 이전에는 '치료할 수 없었던' 표적을 치료할 수 있는 길을 열어주었습니다. 누시넬센(척수성 근위축증 치료제), 파티실란(유전성 트랜스시레틴 매개 아밀로이드증 치료제)과 같은 치료제는 ASO와 siRNA의 임상적 유용성을 검증했습니다. 한편, COVID-19 백신으로 전 세계에서 주목받게된 mRNA 기술은 현재 종양학, 자가면역질환, 개인맞춤형 백신 등에 재사용되고 있습니다. 이러한 변화는 광범위한 개입에서 고도로 개인화된 유전자 수준의 의료로의 전환을 의미합니다.

어떤 기술 발전이 임상 도입과 전달을 지원하고 있는가?

핵산 치료의 성공 여부는 이러한 깨지기 쉬운 분자를 보호하고 세포 특이적 흡수를 가능하게 하는 전달 기술에 달려 있습니다. 지질 나노입자(LNP)는 특히 mRNA 및 siRNA 치료제에서 가장 확장 가능하고 임상적으로 검증된 캐리어로 등장했습니다. 이러한 LNP는 치료제 페이로드를 분해로부터 보호하고, 내피세포 분열을 통해 세포 내로의 침입을 촉진하며, 세포질 내에서 조절된 방출을 유발합니다. 이온화 가능한 지질 디자인, PEG화 전략, 표적화 리간드 등의 개선으로 LNP 시스템의 효능과 안전성이 크게 향상되었습니다.

LNP 외에도 고분자 기반 나노입자, 덴드리머, 엑소좀, GalNAc를 이용한 컨쥬게이트 전달(간 타겟팅용) 등 투여 경로와 표적 조직의 폭을 넓혀가고 있습니다. 예를 들어 GalNAc를 결합시킨 siRNA는 만성 간질환에 대해 월별 투여 스케줄로 피하투여가 가능합니다. 또한 전기천공, 바이러스 벡터(AAV, 렌치바이러스), 새로운 하이드로겔 등이 종양학 및 중추신경계 질환에서 국소 또는 조직 선택적 전달을 위해 테스트되고 있습니다. 생물정보학 툴은 현재 표적 외 영향을 피하고 세포내 안정성을 높이기 위해 서열 설계를 최적화하는 데 있으며, 매우 중요한 역할을 하고 있습니다.

동시에 합성 화학의 발전은 올리고뉴클레오티드 서열의 안정성, 친화력, 면역원성 프로파일을 향상시키고 있습니다. 백본의 변형(포스포로티오네이트 등), 당고리의 변화(2'-O-메틸, 2'-플루오로), 락드핵산(LNA) 구조 등으로 약동학이 개선되어 면역활성화를 최소화하고 있습니다. 이러한 발전은 투여 횟수 증가, 순환 반감기 연장, 독성 프로파일 감소 등 임상 적용 확대와 규제 당국의 승인에 중요한 요소로 작용하고 있습니다.

시장 침투를 주도하는 치료 분야와 기업은?

희귀유전질환, 종양학, 감염질환이 핵산치료제 도입의 최전선에 있습니다. 기존의 저분자 화합물로는 불충분한 경우가 많은 희귀질환에서 ASO와 siRNA는 결함이 있는 유전자 산물을 회복시키거나 침묵시킴으로써 뚜렷한 효과를 보이고 있습니다. 뒤쉔 근이영양증, 근위축성측색경화증(ALS), 바텐병 등의 질환은 임상연구가 활발히 진행되고 있는 주요 타겟 중 하나입니다. 미국과 유럽에서 희귀질환 치료제 지정 및 조기 승인으로 이 분야 개발자들이 더 빨리 시장을 개발할 수 있게 되었습니다.

핵산 치료제는 유전자 침묵, 신항원 백신 개발, 면역세포 초기화 등에 사용되고 있습니다. Moderna, Merck와 같은 거대 제약회사와의 공동개발을 통한 맞춤형 mRNA 암 백신은 흑색종과 폐암에 대한 후기 임상시험을 진행하고 있습니다. 동시에, RNA 간섭 플랫폼은 KRAS, STAT3와 같은 종양 촉진 인자를 침묵시키도록 조정되어 있습니다. 고형암에서 약물전달은 여전히 어려운 과제이지만, 종양내 및 국소 전달 전략을 통해 약물의 분포와 효능이 개선되고 있습니다.

Ionis Pharmaceuticals, Alnylam, Moderna, BioNTech, Sarepta Therapeutics와 같은 주요 기업은 올리고뉴클레오티드의 화학 및 전달에 대한 깊은 전문성을 활용하여 업계를 선도하고 있습니다. 신생 생명공학 기업도 핵산 치료와 AI 기반 약물 설계의 교차점에서 혁신을 추진하고 있습니다. 중국, 한국 등 시장 진출기업은 정책적 지원과 IP 조정을 통해 자국내 개발을 가속화하고 있으며, 세계 치료제 파이프라인에 대한 지역내 진입을 늘리고 있습니다.

세계 핵산 기반 치료제 시장의 성장을 가속하는 요인은 무엇인가?

세계 핵산 기반 치료제 시장의 성장은 유전병에 대한 인식 증가, 백신 플랫폼의 급속한 발전, 정밀의료에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 인간유전체학 및 전사체학에 대한 이해가 깊어짐에 따라 질병 표적과 바이오마커의 식별이 용이해졌고, 핵산 개입을 통한 치료 가능한 적응증 풀이 확대되었습니다.

임상적 성공 사례는 이해관계자들의 의구심을 줄이고 전임상 단계부터 임상 단계까지의 투자를 가속화했습니다. 전략적 제휴, 라이선싱 계약, 벤처 캐피털의 자금 조달이 RNA에 초점을 맞춘 스타트업과 전달 기술 플랫폼에 유입되고 있습니다. COVID-19 mRNA 백신의 성공은 전 세계에서 검증을 받았으며, 의료 시스템과 규제 당국이 향후 유행병, 암 및 신흥 질병에 대한 확장 가능하고 신속한 핵산 요법을 우선순위에 두도록 촉구했습니다.

또한 규제 당국은 특히 미충족 수요가 높은 생명을 위협하는 질환을 대상으로 하는 경우, 이러한 치료법에 대해 보다 명확한 경로와 신속 심사 프로그램을 마련하고 있습니다. 개인 맞춤형 핵산 치료의 고비용에 대응하기 위해 결과 기반 가격 책정 및 가치 기반 계약에 기반한 상환 모델도 진화하고 있습니다. 제조 능력의 확대, 약물 설계의 디지털화, 치료 방법의 다양화로 인해 핵산 기반 치료는 틈새 생명공학 용도에서 21세기 의료의 기본 기둥으로 전환되고 있습니다.

부문

제품(RNA 간섭·단쇄간섭 RNA, 안티센스 올리고뉴클레오티드, 기타 제품), 용도(자가면역질환 용도, 감염증 용도, 유전자 질환 용도, 암용도, 기타 용도), 최종사용자(병원·클리닉 최종사용자, 학술·연구기관 최종사용자)

조사 대상 기업의 예

  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arrowhead Pharmaceuticals
  • BioNTech SE
  • BridgeBio Pharma
  • CureVac N.V.
  • Dicerna Pharmaceuticals
  • Dynavax Technologies
  • Gilead Sciences Inc.
  • Ionis Pharmaceuticals
  • Moderna Inc.
  • NOXXON Pharma N.V.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Phio Pharmaceuticals Corp.
  • Precision BioSciences
  • ProQR Therapeutics N.V.
  • Sarepta Therapeutics
  • Silence Therapeutics
  • Wave Life Sciences

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.09.03

Global Nucleic Acid Based Therapeutics Market to Reach US$12.6 Billion by 2030

The global market for Nucleic Acid Based Therapeutics estimated at US$5.4 Billion in the year 2024, is expected to reach US$12.6 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2024-2030. RNA Interference & Short Interfering RNAs, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$8.5 Billion by the end of the analysis period. Growth in the Antisense Oligonucleotides segment is estimated at 13.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 20.2% CAGR

The Nucleic Acid Based Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.0% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.

Global Nucleic Acid Based Therapeutics Market - Key Trends & Drivers Summarized

How Are Nucleic Acid Therapeutics Redefining the Future of Disease Treatment?

Nucleic acid based therapeutics are reshaping modern medicine by enabling precise manipulation of gene expression and cellular function. These therapies, which include antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, and messenger RNAs (mRNAs), offer targeted intervention at the genetic level, bypassing conventional protein-focused approaches. Unlike traditional drugs that modulate protein pathways post-translation, nucleic acid therapeutics intervene earlier-at the transcription or translation stage-enabling profound specificity in correcting genetic dysfunctions.

This transformative approach has opened doors to treating previously “undruggable” targets such as non-coding RNAs, gene fusions, and rare monogenic diseases. Therapies like nusinersen (for spinal muscular atrophy) and patisiran (for hereditary transthyretin-mediated amyloidosis) have validated the clinical viability of ASOs and siRNAs. Meanwhile, mRNA technologies-propelled to global attention by COVID-19 vaccines-are now being repurposed for oncology, autoimmune conditions, and personalized vaccines. This shift marks a transition from broad-spectrum interventions to highly individualized, gene-level medicine.

What Technological Advances Are Supporting Clinical Translation and Delivery?

The success of nucleic acid therapies hinges on delivery technologies that protect these fragile molecules and enable cell-specific uptake. Lipid nanoparticles (LNPs) have emerged as the most scalable and clinically validated carriers, particularly for mRNA and siRNA drugs. These LNPs shield therapeutic payloads from degradation, facilitate cellular entry via endocytosis, and trigger controlled release in the cytosol. Improvements in ionizable lipid design, PEGylation strategies, and targeting ligands have significantly boosted the efficacy and safety of LNP systems.

Beyond LNPs, polymer-based nanoparticles, dendrimers, exosomes, and conjugated delivery using GalNAc (for liver targeting) are expanding the range of administration routes and target tissues. For example, GalNAc-conjugated siRNAs have enabled subcutaneous administration for chronic liver conditions with monthly dosing schedules. Additionally, electroporation, viral vectors (AAV, lentivirus), and novel hydrogels are being tested for localized or tissue-selective delivery in oncology and CNS disorders. Bioinformatics tools now play a pivotal role in optimizing sequence design to avoid off-target effects and enhance intracellular stability.

Simultaneously, synthetic chemistry advancements are enhancing the stability, affinity, and immunogenicity profiles of oligonucleotide sequences. Backbone modifications (e.g., phosphorothioate), sugar ring alterations (2’-O-methyl, 2’-fluoro), and locked nucleic acid (LNA) architectures have improved pharmacokinetics and minimized immune activation. These advancements are enabling more frequent dosing, longer circulation half-lives, and reduced toxicity profiles-critical factors in expanding clinical adoption and regulatory acceptance.

Which Therapeutic Areas and Companies Are Driving Market Penetration?

Rare genetic diseases, oncology, and infectious diseases are at the forefront of nucleic acid therapeutic adoption. In rare diseases, where traditional small molecules often fall short, ASOs and siRNAs have demonstrated remarkable efficacy by restoring or silencing faulty gene products. Disorders such as Duchenne muscular dystrophy, amyotrophic lateral sclerosis (ALS), and Batten disease are among the key targets under active clinical investigation. The orphan drug designation and accelerated approval pathways in the U.S. and Europe are enabling faster market entry for developers in this segment.

Oncology represents a fast-emerging application area, with nucleic acid therapeutics being employed in gene silencing, neoantigen vaccine development, and immune cell reprogramming. Personalized mRNA cancer vaccines, developed in collaboration between pharma giants like Moderna and Merck, are advancing into late-stage trials for melanoma and lung cancer. Simultaneously, RNA interference platforms are being tailored to silence tumor drivers such as KRAS and STAT3. Delivery challenges in solid tumors remain a hurdle, but intratumoral and local delivery strategies are improving drug distribution and efficacy.

Leading players such as Ionis Pharmaceuticals, Alnylam, Moderna, BioNTech, and Sarepta Therapeutics dominate the landscape, leveraging deep expertise in oligonucleotide chemistry and delivery. Emerging biotechs are also innovating at the intersection of nucleic acid therapy and AI-driven drug design. Markets such as China and South Korea are accelerating homegrown development through policy support and IP harmonization, increasing regional participation in the global therapeutic pipeline.

What Is Fueling Growth in the Global Nucleic Acid Based Therapeutics Market?

The growth in the global nucleic acid based therapeutics market is driven by several factors, including rising genetic disease awareness, rapid vaccine platform development, and the growing demand for precision medicine. Increased understanding of human genomics and transcriptomics has enabled better identification of disease targets and biomarkers, expanding the pool of treatable indications through nucleic acid interventions.

Clinical success stories have reduced stakeholder skepticism and accelerated investments across preclinical and clinical stages. Strategic collaborations, licensing deals, and venture capital funding are flowing into RNA-focused startups and delivery technology platforms. The success of COVID-19 mRNA vaccines served as a global validation event, prompting healthcare systems and regulators to prioritize scalable and rapid-response nucleic acid therapies for future pandemics, cancer, and emerging diseases.

Moreover, regulatory agencies have established clearer pathways and expedited review programs for these therapies, especially when targeting life-threatening conditions with high unmet needs. Reimbursement models are evolving to accommodate the high costs of personalized nucleic acid therapies, supported by outcome-based pricing and value-based contracting. With expanding manufacturing capacity, digital drug design, and increasing therapeutic diversity, nucleic acid based therapeutics are transitioning from niche biotech applications to a foundational pillar of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Based Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides, Other Products); Application (Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application, Other Applications) End-User (Hospitals & Clinics End-User, Academic & Research Institutes End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arrowhead Pharmaceuticals
  • BioNTech SE
  • BridgeBio Pharma
  • CureVac N.V.
  • Dicerna Pharmaceuticals
  • Dynavax Technologies
  • Gilead Sciences Inc.
  • Ionis Pharmaceuticals
  • Moderna Inc.
  • NOXXON Pharma N.V.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Phio Pharmaceuticals Corp.
  • Precision BioSciences
  • ProQR Therapeutics N.V.
  • Sarepta Therapeutics
  • Silence Therapeutics
  • Wave Life Sciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nucleic Acid Based Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Genetic and Rare Disease Research Throws the Spotlight on Nucleic Acid Based Therapeutics
    • Rapid Advancement in mRNA Technology Drives Breakthroughs Beyond Vaccines
    • Expansion of CRISPR and RNAi Platforms Strengthens Business Case for Nucleic Acid-Based Interventions
    • Development of Stabilized Oligonucleotides Enhances Therapeutic Efficacy and Shelf Life
    • Partnerships Between Biotech Startups and Pharma Giants Propel Pipeline Expansion
    • Regulatory Flexibility for Orphan and Breakthrough Therapies Accelerates Clinical Advancements
    • Integration of Targeted Delivery Systems Boosts Precision and Minimizes Off-Target Effects
    • Rise in Next-Generation Sequencing Capabilities Enhances Target Identification and Customization
    • Government Funding for Rare and Genetic Disorders Drives Market Entry for Nucleic Acid Therapies
    • Growing Role of AI in RNA Structure Prediction Accelerates Discovery and Development Cycles
    • Advances in Non-Viral Delivery Mechanisms Open New Pathways for Nucleic Acid-Based Drug Platforms
    • Embrace of Modular Chemistry Accelerates Scalable Production of Oligo-Based Therapeutics
    • Positive Clinical Data for Antisense and siRNA Candidates Spurs Investor Confidence
    • Emergence of Self-Amplifying RNA and Circular RNA Expands Therapeutic Potential
    • Global Demand for Pandemic-Responsive Drug Platforms Sustains Investment in RNA Toolkits
    • Rising Patient Advocacy for Genetic Cure Options Propels Demand for Novel Therapeutic Modalities
    • Integration of Companion Diagnostics Enhances Clinical and Commercial Success
    • Market Entry of CDMO Players With RNA Expertise Fuels End-to-End Development Pipelines
    • Pursuit of Multi-Target and Multi-Pathway Therapies Expands Use Cases for Nucleic Acid Drugs
    • Growing Use in Oncology, CNS, and Infectious Disease Broadens Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nucleic Acid Based Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for RNA Interference & Short Interfering RNAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for RNA Interference & Short Interfering RNAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antisense Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antisense Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Genetic Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Genetic Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • JAPAN
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • CHINA
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • EUROPE
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • FRANCE
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • GERMANY
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • INDIA
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Nucleic Acid Based Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • AFRICA
    • Nucleic Acid Based Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Nucleic Acid Based Therapeutics by Product - RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Product - Percentage Breakdown of Value Sales for RNA Interference & Short Interfering RNAs, Antisense Oligonucleotides and Other Products for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Nucleic Acid Based Therapeutics by Application - Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Nucleic Acid Based Therapeutics by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application, Infectious Diseases Application, Genetic Disorders Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제